| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9956428 | International Journal of Cardiology | 2005 | 6 Pages |
Abstract
The IC administration of abciximab bolus acutely decreases CTFC through culprit vessels of patients with ACS undergoing urgent PCI. Further studies evaluating the potential clinical benefits associated with IC abciximab administration are warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Enrico Romagnoli, Francesco Burzotta, Carlo Trani, Mario A. Mazzari, Giuseppe G.L. Biondi-Zoccai, Maria De Vita, Floriana Giannico, Giampaolo Niccoli, Francesco Prati, Antonio G. Rebuzzi, Rocco Mongiardo, Filippo Crea,